Mean level ± SD at end of period | Mean differences (95% CI) | P-value | ||||
---|---|---|---|---|---|---|
N | Baseline | 5 weeks | 5 weeks minus baseline | Double difference (rostafuroxin minus placebo) | ||
Systolic pressure, mm Hg | ||||||
Placebo | 189 | 137.8 ± 10.7 | 135.6 ± 12.2 | -2.28 (-3.78 to -0.77) | ||
Rostafuroxin | ||||||
0.05 mg | 39 | 137.3 ± 11.3 | 132.5 ± 11.2 | -4.74 (-8.00 to -1.48) | -1.16 (-5.38 to 3.06) | 0.59 |
0.15 mg | 36 | 134.9 ± 10.9 | 137.3 ± 11.2 | +2.36 (-0.62 to 5.34) | 3.16 (-1.32 to 7.63) | 0.16 |
0.5 mg | 38 | 137.4 ± 9.6 | 136.7 ± 9.9 | -0.76 (-4.44 to 2.92) | 2.63 (-2.44 to 7.70) | 0.30 |
1.5 mg | 40 | 137.8 ± 11.8 | 138.0 ± 10.3 | +0.21 (-3.10 to 3.51) | 2.12 (-2.74 to 6.98) | 0.39 |
5.0 mg | 36 | 136.2 ± 11.7 | 135.6 ± 11.9 | -0.52 (-4.32 to 3.27) | 1.33 (-4.00 to 6.66) | 0.62 |
All doses | 189 | 136.8 ± 11.0 | 136.0 ± 11.0 | -0.74 (-2.24 to 0.77) | 1.54 (-0.59 to 3.66) | 0.16 |
Diastolic pressure, mm Hg | ||||||
Placebo | 189 | 86.2 ± 7.8 | 84.0 ± 8.7 | -2.28 (-3.28 to -1.28) | ||
Rostafuroxin | ||||||
0.05 mg | 39 | 84.1 ± 7.2 | 82.4 ± 8.4 | -1.65 (-3.25 to -0.06) | 1.62 (-0.74 to 3.97) | 0.18 |
0.15 mg | 36 | 84.2 ± 8.4 | 84.6 ± 9.1 | +0.41 (-1.46 to 2.28) | 1.62 (-1.23 to 4.47) | 0.26 |
0.5 mg | 38 | 87.6 ± 8.8 | 85.7 ± 8.3 | -1.89 (-4.15 to 0.37) | 0.68 (-2.65 to 4.01) | 0.68 |
1.5 mg | 40 | 85.6 ± 8.4 | 85.4 ± 7.4 | -0.28 (-1.96 to 1.40) | 1.64 (-1.21 to 4.50) | 0.25 |
5.0 mg | 36 | 85.0 ± 9.0 | 85.4 ± 8.4 | +0.36 (-2.34 to 3.07) | 2.85 (-0.86 to 6.57) | 0.13 |
All doses | 189 | 85.3 ± 8.4 | 84.7 ± 8.3 | -0.63 (-1.52 to 0.26) | 1.65 (0.31 to 2.98) | 0.02 |